Lord, Abbett & Co. LLC Iovance Biotherapeutics, Inc. Transaction History

Lord, Abbett & Co. LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$16.33 - $33.07 $17.9 Million - $36.3 Million	-1,097,031 Closed	0 $0
Q1 2021 May 11, 2021	SELL	$28.67 - $52.59 $59.8 Million - $110 Million	-2,087,457 Reduced 65.55%	1,097,031 $34.7 Million
Q4 2020 Feb 09, 2021	BUY	$28.04 - $50.26 $37.5 Million - $67.3 Million	1,338,048 Added 72.47%	3,184,488 $148 Million
Q3 2020 Nov 12, 2020	BUY	$27.75 - $36.3 $1.92 Million - $2.52 Million	69,311 Added 3.9%	1,846,440 $60.8 Million
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $32.1 Million - $48.4 Million	1,180,398 Added 197.81%	1,777,129 $48.8 Million
Q1 2020 May 14, 2020	BUY	$19.54 - $38.85 $11.7 Million - $23.2 Million	596,731 New	596,731 $17.9 Million

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.28B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.